-
1
-
-
0027434291
-
Effects of gemfibrozil on triglyceride levels in patients with NIDDM
-
Vinik A.I., Colwell J.A. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Diab. Care. 16:(1):1993;37-44.
-
(1993)
Diab. Care
, vol.16
, Issue.1
, pp. 37-44
-
-
Vinik, A.I.1
Colwell, J.A.2
-
2
-
-
0027499264
-
Lipoprotein abnormalities in well-treated Type II diabetic patients
-
Manzato E., Zambon A., Lapolla A., Zambon S., Braghetto L., Crepaldi G., Fedele D. Lipoprotein abnormalities in well-treated Type II diabetic patients. Diab. Care. 16:(2):1993;469-475.
-
(1993)
Diab. Care
, vol.16
, Issue.2
, pp. 469-475
-
-
Manzato, E.1
Zambon, A.2
Lapolla, A.3
Zambon, S.4
Braghetto, L.5
Crepaldi, G.6
Fedele, D.7
-
3
-
-
0343532337
-
Clinical Practice Recommendations 1998
-
American Diabetes Association
-
American Diabetes Association. Clinical Practice Recommendations 1998. Diabetes Care 1998;21 (Suppl 1) 179-182.
-
(1998)
Diabetes Care
, vol.21
, Issue.SUPPL. 1
, pp. 179-182
-
-
-
4
-
-
0027192174
-
Detection and management of lipid disorders in diabetes
-
Consensus Statement
-
Consensus Statement. Detection and management of lipid disorders in diabetes. Diab. Care 1993;16 (2):106-112.
-
(1993)
Diab. Care
, vol.16
, Issue.2
, pp. 106-112
-
-
-
5
-
-
0029112532
-
Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia
-
Raskin P., Ganda O.P., Schwartz S., Willard D., Rosenstock J., Lodewick P.A., Cressman M.D., Phillipson B., Weiner B., McGovern M.E., et al. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Am. J. Med. 99:1995;362-369.
-
(1995)
Am. J. Med.
, vol.99
, pp. 362-369
-
-
Raskin, P.1
Ganda, O.P.2
Schwartz, S.3
Willard, D.4
Rosenstock, J.5
Lodewick, P.A.6
Cressman, M.D.7
Phillipson, B.8
Weiner, B.9
McGovern, M.E.10
-
6
-
-
0029891503
-
Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes
-
Best J.D., Nicholson G.C., O'Neal D.N., Kotowicz M.A., Tebbutt N.C., Chan D.-W., Sanders K.M. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diab. Nutr. Med. 9:1999;74-80.
-
(1999)
Diab. Nutr. Med.
, vol.9
, pp. 74-80
-
-
Best, J.D.1
Nicholson, G.C.2
O'Neal, D.N.3
Kotowicz, M.A.4
Tebbutt, N.C.5
Chan, D.-W.6
Sanders, K.M.7
-
7
-
-
1842326783
-
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
-
Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diab Care 1997;20(4):614-620.
-
(1997)
Diab Care
, vol.20
, Issue.4
, pp. 614-620
-
-
Pyorala, K.1
Pedersen, T.R.2
Kjekshus, J.3
Faergeman, O.4
Olsson, A.G.5
Thorgeirsson, G.6
-
8
-
-
0342981862
-
Braunwald E for the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
-
Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R. Braunwald E for the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335:1996;1001-1009.
-
(1996)
New Engl. J. Med.
, vol.335
, pp. 1001-1009
-
-
Sacks, F.M.1
Pfeffer, M.A.2
Moye, L.A.3
Rouleau, J.L.4
Rutherford, J.D.5
Cole, T.G.6
Brown, L.7
Warnica, J.W.8
Arnold, J.M.9
Wun, C.C.10
Davis, B.R.11
-
9
-
-
0032560807
-
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
-
Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl. J. Med. 339:1998;229-234.
-
(1998)
New Engl. J. Med.
, vol.339
, pp. 229-234
-
-
Haffner, S.M.1
Lehto, S.2
Ronnemaa, T.3
Pyorala, K.4
Laakso, M.5
-
10
-
-
0001434733
-
Expert Panel: Summary of the second report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol (Adult treatment panel II)
-
National Cholesterol Education Program (NCEP)
-
National Cholesterol Education Program (NCEP) Expert Panel: Summary of the second report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol (Adult treatment panel II). J Am Med Assoc 1993;209:3015-3023.
-
(1993)
J Am Med Assoc
, vol.209
, pp. 3015-3023
-
-
-
11
-
-
0031975337
-
Management of dyslipidemia in adults with diabetes
-
American Diabetes Association
-
American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diab. Care 1998;21:179-182.
-
(1998)
Diab. Care
, vol.21
, pp. 179-182
-
-
-
12
-
-
0032515775
-
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
-
Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., Holman R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). Br. Med. J. 316:1998;823-828.
-
(1998)
Br. Med. J.
, vol.316
, pp. 823-828
-
-
Turner, R.C.1
Millns, H.2
Neil, H.A.3
Stratton, I.M.4
Manley, S.E.5
Matthews, D.R.6
Holman, R.R.7
-
14
-
-
0010420182
-
Effectiveness of atorvastatin in treating patients to LDL-C goals compared with lovastatin, pravastatin and simvastatin
-
Nawrocki J., Shurzinske L., Black D.M. Effectiveness of atorvastatin in treating patients to LDL-C goals compared with lovastatin, pravastatin and simvastatin. Atherosclerosis. 134:1997;120.
-
(1997)
Atherosclerosis
, vol.134
, pp. 120
-
-
Nawrocki, J.1
Shurzinske, L.2
Black, D.M.3
-
15
-
-
0029043903
-
Reduction of LDL cholesterol by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
-
Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15:(5):1995;678-682.
-
(1995)
Arterioscler. Thromb. Vasc. Biol.
, vol.15
, Issue.5
, pp. 678-682
-
-
Nawrocki, J.W.1
Weiss, S.R.2
Davidson, M.H.3
Sprecher, D.L.4
Schwartz, S.L.5
Lupien, P.J.6
Jones, P.H.7
Haber, H.E.8
Black, D.M.9
-
16
-
-
0032464095
-
A multicenter, placebo-controlled, dose-ranging study of atorvastatin
-
Schrott H., Gmerek A., Fereshetian A., Knopp R.H., Bays H., Jones P.H., Littlejohn T.W., McLain R., Black D.M. A multicenter, placebo-controlled, dose-ranging study of atorvastatin. J. Cardiovasc. Pharmacol. Therapeut. 3:(2):1998;119-124.
-
(1998)
J. Cardiovasc. Pharmacol. Therapeut.
, vol.3
, Issue.2
, pp. 119-124
-
-
Schrott, H.1
Gmerek, A.2
Fereshetian, A.3
Knopp, R.H.4
Bays, H.5
Jones, P.H.6
Littlejohn, T.W.7
McLain, R.8
Black, D.M.9
-
18
-
-
0000677439
-
Estimation of the concentration of low density lipoproteins cholesterol in plasma without the use of the ultracentrifuge
-
Friedewald W.T., Levy I.R., Fredrickson D.S. Estimation of the concentration of low density lipoproteins cholesterol in plasma without the use of the ultracentrifuge. Clin. Chem. 18:1972;449-502.
-
(1972)
Clin. Chem.
, vol.18
, pp. 449-502
-
-
Friedewald, W.T.1
Levy, I.R.2
Fredrickson, D.S.3
-
19
-
-
0002943799
-
Lipid and lipoprotein analysis
-
Washington DC: US Department of Health, Education and Welfare publication NIH 75-628
-
Lipid and lipoprotein analysis. In: Manual of laboratory Operations: Lipid Research Clinics Program Report. Washington DC: 1974. US Department of Health, Education and Welfare publication NIH 75-628, Vol 1.
-
(1974)
In: Manual of Laboratory Operations: Lipid Research Clinics Program Report
, vol.1
-
-
-
20
-
-
0032032592
-
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
-
Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81:1988;582-587.
-
(1988)
Am. J. Cardiol.
, vol.81
, pp. 582-587
-
-
Jones, P.1
Kafonek, S.2
Laurora, I.3
Hunninghake, D.4
-
21
-
-
7344240413
-
The cost of reaching National Cholesterol Education Panel (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin
-
Koren M.J., Smith D.G., Hunninghake D.B., Davidson M.H., McKenney J.M., Weiss S.R., Schrott H.G., Henley Jr R.W., Tresh P., McLain R.W., Bakker-Arkema R.G., Black D.M. The cost of reaching National Cholesterol Education Panel (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 14:1998;59-70.
-
(1998)
Pharmacoeconomics
, vol.14
, pp. 59-70
-
-
Koren, M.J.1
Smith, D.G.2
Hunninghake, D.B.3
Davidson, M.H.4
McKenney, J.M.5
Weiss, S.R.6
Schrott, H.G.7
Henley Jr, R.W.8
Tresh, P.9
McLain, R.W.10
Bakker-Arkema, R.G.11
Black, D.M.12
-
22
-
-
4243407053
-
Efficacy and safety of atorvastatin in hyperlipidemic patients with concurrent hypertension or non-insulin-dependent diabetes mellitus
-
7-11 June Amsterdam
-
Black DM, Bakker-Arkema R, Heinonen T, Nawrocki JW. Efficacy and safety of atorvastatin in hyperlipidemic patients with concurrent hypertension or non-insulin-dependent diabetes mellitus. Presented at the International Society of Hypertension, 7-11 June 1998, Amsterdam.
-
(1998)
Presented at the International Society of Hypertension
-
-
Black, D.M.1
Bakker-Arkema, R.2
Heinonen, T.3
Nawrocki, J.W.4
-
23
-
-
0030967489
-
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I
-
Davidson M., McKenney J., Stein E., Schrott H., Bakker-Arkema R., Fayyad R., Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am. J. Cardiol. 79:(11):1997;1475-1481.
-
(1997)
Am. J. Cardiol.
, vol.79
, Issue.11
, pp. 1475-1481
-
-
Davidson, M.1
McKenney, J.2
Stein, E.3
Schrott, H.4
Bakker-Arkema, R.5
Fayyad, R.6
Black, D.7
-
24
-
-
18544412108
-
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
-
Bertolini S., Bon G.B., Campbell L.M., Farnier M., Langan J., Mahla G., Pauciullo P., Sirtori C., Egros F., Fayyad R., Nawrocki J.W. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 130:(1-2):1997;191-197.
-
(1997)
Atherosclerosis
, vol.130
, Issue.12
, pp. 191-197
-
-
Bertolini, S.1
Bon, G.B.2
Campbell, L.M.3
Farnier, M.4
Langan, J.5
Mahla, G.6
Pauciullo, P.7
Sirtori, C.8
Egros, F.9
Fayyad, R.10
Nawrocki, J.W.11
-
25
-
-
0031195278
-
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
-
Dart A., Jerums G., Nicholson G., d'Emden M., Hamilton-Craig I., Tallis G., Best J., West M., Sullivan D., Bracs P., Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardiol. 80:(1):1997;39-44.
-
(1997)
Am. J. Cardiol.
, vol.80
, Issue.1
, pp. 39-44
-
-
Dart, A.1
Jerums, G.2
Nicholson, G.3
D'Emden, M.4
Hamilton-Craig, I.5
Tallis, G.6
Best, J.7
West, M.8
Sullivan, D.9
Bracs, P.10
Black, D.11
-
26
-
-
0032568086
-
Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in familial combined hypercholesterolemia
-
Schonfeld G., Aguilar-Salinas C.A., Nizar E. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in familial combined hypercholesterolemia. Am. J. Cardiol. 81:(4A):1998;43B-46B.
-
(1998)
Am. J. Cardiol.
, vol.81
, Issue.4 A
-
-
Schonfeld, G.1
Aguilar-Salinas, C.A.2
Nizar, E.3
-
27
-
-
0002013221
-
Effect of atorvastatin on serum levels of lipoproteins in French Canadians with homozygous or compound heterozygous familial hypercholesterolemia
-
Couture P., Gaudet D., Brun D., Bergeron J., Cantin L., Black O., Gagné C. Effect of atorvastatin on serum levels of lipoproteins in French Canadians with homozygous or compound heterozygous familial hypercholesterolemia. Atherosclerosis. 134:1997;54-59.
-
(1997)
Atherosclerosis
, vol.134
, pp. 54-59
-
-
Couture, P.1
Gaudet, D.2
Brun, D.3
Bergeron, J.4
Cantin, L.5
Black, O.6
Gagné, C.7
-
28
-
-
0030716524
-
Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia
-
Marais A.D., Naoumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38:(10):1997;2071-2078.
-
(1997)
J. Lipid Res.
, vol.38
, Issue.10
, pp. 2071-2078
-
-
Marais, A.D.1
Naoumova, R.P.2
Firth, J.C.3
Penny, C.4
Neuwirth, C.K.5
Thompson, G.R.6
-
29
-
-
0343968223
-
-
Data on file. Parke-Davis Pharmaceutical Research Division. Warner-Lambert Company, Ann Arbor, Michigan
-
Data on file. Parke-Davis Pharmaceutical Research Division. Warner-Lambert Company, Ann Arbor, Michigan.
-
-
-
-
30
-
-
0031454724
-
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia
-
Raal F., Pilcher G., Illingworth R., Pappu A., Stein E., Laskarzewski P., Mitchel Y., Melino M. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis. 135:1997;249-256.
-
(1997)
Atherosclerosis
, vol.135
, pp. 249-256
-
-
Raal, F.1
Pilcher, G.2
Illingworth, R.3
Pappu, A.4
Stein, E.5
Laskarzewski, P.6
Mitchel, Y.7
Melino, M.8
-
31
-
-
0029793477
-
Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence
-
Pyorala K., Steiner G. Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence. Ann. Med. 28:(4):1996;357-362.
-
(1996)
Ann. Med.
, vol.28
, Issue.4
, pp. 357-362
-
-
Pyorala, K.1
Steiner, G.2
-
32
-
-
0023726344
-
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
-
Manninen V., Elo M.O., Frick M.H., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J. Am. Med. Assoc. 260:1988;641-651.
-
(1988)
J. Am. Med. Assoc.
, vol.260
, pp. 641-651
-
-
Manninen, V.1
Elo, M.O.2
Frick, M.H.3
Haapa, K.4
Heinonen, O.P.5
Heinsalmi, P.6
Helo, P.7
Huttunen, J.K.8
Kaitaniemi, P.9
Koskinen, P.10
|